HEALTHMay 28 · 18:48 UTCSTAT NEWSAdam Feuerstein, Allison DeAngelis, and Elaine Chen

STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk

Jeremy Levin, founder of Ovid Therapeutics and former CEO of Teva Pharmaceuticals, argues in his book that political upheaval, weakening institutions, and short-term investing threaten the biotech industry's future despite scientific advancements. He advocates for federal policy changes to support biotech investment and for pharmaceutical companies to address regulatory challenges.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Jeremy LevinpersonOvid TherapeuticsorganizationTeva PharmaceuticalsorganizationBiotech in the Balance: Saving a Strategic Industry in an Age of Distrusttopicregulatory upheavaltopicpharmaceutical companiesorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 20 · 13:55 UTC
STAT+: Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more
HEALTHMay 28 · 18:20 UTC
Biotech exec Jeremy Levin on the industry’s strategic turning point
BUSINESSMay 12 · 08:30 UTC
Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
BUSINESSMay 18 · 13:11 UTC
STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
BUSINESSMay 6 · 14:42 UTC
COVID pioneer BioNTech: The fall of Germany's pandemic hero
BUSINESSMay 18 · 08:30 UTC
STAT+: The China question is tearing biotech apart